| Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ... Nature genetics 45 (11), 1353-1360, 2013 | 1387 | 2013 |
| Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility International Multiple Sclerosis Genetics Consortium*†, ANZgene, ... Science 365 (6460), eaav7188, 2019 | 1084 | 2019 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1083 | 2018 |
| Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models E Cekanaviciute, BB Yoo, TF Runia, JW Debelius, S Singh, CA Nelson, ... Proceedings of the National Academy of Sciences 114 (40), 10713-10718, 2017 | 1009 | 2017 |
| Treatment of multiple sclerosis: a review SL Hauser, BAC Cree The American journal of medicine 133 (12), 1380-1390. e2, 2020 | 932 | 2020 |
| An open label study of the effects of rituximab in neuromyelitis optica BAC Cree, S Lamb, K Morgan, A Chen, E Waubant, C Genain Neurology 64 (7), 1270-1272, 2005 | 768 | 2005 |
| Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and … A Rae-Grant, GS Day, RA Marrie, A Rabinstein, BAC Cree, GS Gronseth, ... Neurology 90 (17), 777-788, 2018 | 675 | 2018 |
| Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial BAC Cree, JL Bennett, HJ Kim, BG Weinshenker, SJ Pittock, ... The Lancet 394 (10206), 1352-1363, 2019 | 658 | 2019 |
| Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis SE Baranzini, J Wang, RA Gibson, N Galwey, Y Naegelin, F Barkhof, ... Human molecular genetics 18 (4), 767-778, 2009 | 588 | 2009 |
| Treatment of neuromyelitis optica with rituximab A Jacob, BG Weinshenker, I Violich, N McLinskey, L Krupp, RJ Fox, ... Arch Neurol 65 (11), 1443-8, 2008 | 545 | 2008 |
| Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial AJ Green, JM Gelfand, BA Cree, C Bevan, WJ Boscardin, F Mei, J Inman, ... The Lancet 390 (10111), 2481-2489, 2017 | 544 | 2017 |
| Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial F Lublin, DH Miller, MS Freedman, BAC Cree, JS Wolinsky, H Weiner, ... The Lancet 387 (10023), 1075-1084, 2016 | 510 | 2016 |
| Long‐term evolution of multiple sclerosis disability in the treatment era University of California, San Francisco MS‐EPIC Team:, BAC Cree, ... Annals of neurology 80 (4), 499-510, 2016 | 446 | 2016 |
| Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis LF Barcellos, S Sawcer, PP Ramsay, SE Baranzini, G Thomson, F Briggs, ... Human molecular genetics 15 (18), 2813-2824, 2006 | 408 | 2006 |
| Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans JR Oksenberg, LF Barcellos, BAC Cree, SE Baranzini, TL Bugawan, ... The American Journal of Human Genetics 74 (1), 160-167, 2004 | 401 | 2004 |
| Silent progression in disease activity–free relapsing multiple sclerosis University of California, San Francisco MS‐EPIC Team, BAC Cree, ... Annals of neurology 85 (5), 653-666, 2019 | 366 | 2019 |
| Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis BAC Cree, O Khan, D Bourdette, DS Goodin, JA Cohen, RA Marrie, ... Neurology 63 (11), 2039-2045, 2004 | 364 | 2004 |
| Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’(NEDA-4) in relapsing–remitting multiple sclerosis L Kappos, N De Stefano, MS Freedman, BAC Cree, EW Radue, ... Multiple Sclerosis Journal 22 (10), 1297-1305, 2016 | 362 | 2016 |
| Aquaporin 4‐specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter M Varrin‐Doyer, CM Spencer, U Schulze‐Topphoff, PA Nelson, ... Annals of neurology 72 (1), 53-64, 2012 | 347 | 2012 |
| Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2 U Schulze-Topphoff, M Varrin-Doyer, K Pekarek, CM Spencer, A Shetty, ... Proceedings of the National Academy of Sciences 113 (17), 4777-4782, 2016 | 320 | 2016 |
Stephen L. HauserUCSFZweryfikowany adres z ucsf.edu
